OBJECTIVE: Adrenonodular hyperplasia and tumour formation are potential long-term complications of congenital adrenal hyperplasia (CAH) with little known regarding the clinical implications. Our aim was to describe volumetric adrenal morphology and determine the association between radiological findings and comorbidities in adults with classic CAH. DESIGN: This was a cross-sectional study of 88 patients (mean age 29.2 ± 13 years, 47 females) with classic CAH seen in a tertiary referral centre. METHODS: CT imaging, performed at study entry or when reaching adulthood, was used to create 3-dimensional volumetric models. Clinical, genetic and hormonal evaluations were collected and correlated with adrenal morphology and tumour formation. RESULTS: Over one-third of the cohort was obese. 53% had elevated 17-OH-progesterone or androstenedione; and 60% had adrenal hyperplasia. Tumours included 11 myelolipomas, 8 benign adrenocortical adenomas, 1 pheochromocytoma and 50% of men had testicular adrenal rest tissue. CAH patients with adrenal hyperplasia had significantly higher number of comorbidities than those with morphologically normal adrenals (P = 0.03). Variables that positively correlated with adrenal volume included hypogonadal/oligomenorrhoeic status, hypertension, androstenedione, aldosterone, and triglyceride levels, and in women, low HDL and insulin resistance. Elevated aldosterone was observed in a subset of patients with simple virilizing CAH. CONCLUSIONS: Adrenocortical hyperplasia is associated with a number of comorbidities, especially hypogonadism. Aldosterone production associated with adrenal enlargement may play a role in the development of metabolic risk factors. Further studies are needed to assess the long-term impact of the excess adrenal steroid milieu associated with adrenal enlargement to develop improved management strategies for CAH. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
OBJECTIVE:Adrenonodular hyperplasia and tumour formation are potential long-term complications of congenital adrenal hyperplasia (CAH) with little known regarding the clinical implications. Our aim was to describe volumetric adrenal morphology and determine the association between radiological findings and comorbidities in adults with classic CAH. DESIGN: This was a cross-sectional study of 88 patients (mean age 29.2 ± 13 years, 47 females) with classic CAH seen in a tertiary referral centre. METHODS: CT imaging, performed at study entry or when reaching adulthood, was used to create 3-dimensional volumetric models. Clinical, genetic and hormonal evaluations were collected and correlated with adrenal morphology and tumour formation. RESULTS: Over one-third of the cohort was obese. 53% had elevated 17-OH-progesterone or androstenedione; and 60% had adrenal hyperplasia. Tumours included 11 myelolipomas, 8 benign adrenocortical adenomas, 1 pheochromocytoma and 50% of men had testicular adrenal rest tissue. CAH patients with adrenal hyperplasia had significantly higher number of comorbidities than those with morphologically normal adrenals (P = 0.03). Variables that positively correlated with adrenal volume included hypogonadal/oligomenorrhoeic status, hypertension, androstenedione, aldosterone, and triglyceride levels, and in women, low HDL and insulin resistance. Elevated aldosterone was observed in a subset of patients with simple virilizing CAH. CONCLUSIONS:Adrenocortical hyperplasia is associated with a number of comorbidities, especially hypogonadism. Aldosterone production associated with adrenal enlargement may play a role in the development of metabolic risk factors. Further studies are needed to assess the long-term impact of the excess adrenal steroid milieu associated with adrenal enlargement to develop improved management strategies for CAH. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
Authors: D P Merke; G P Chrousos; G Eisenhofer; M Weise; M F Keil; A D Rogol; J J Van Wyk; S R Bornstein Journal: N Engl J Med Date: 2000-11-09 Impact factor: 91.245
Authors: Nicole Reisch; Michael Scherr; Linda Flade; Martin Bidlingmaier; Hans-Peter Schwarz; Ullrich Müller-Lisse; Martin Reincke; Marcus Quinkler; Felix Beuschlein Journal: J Clin Endocrinol Metab Date: 2010-02-26 Impact factor: 5.958
Authors: Juan F Ascaso; Susana Pardo; José T Real; Rosario I Lorente; Antonia Priego; Rafael Carmena Journal: Diabetes Care Date: 2003-12 Impact factor: 19.112
Authors: Miguel Debono; Cyrus Ghobadi; Amin Rostami-Hodjegan; Hiep Huatan; Michael J Campbell; John Newell-Price; Ken Darzy; Deborah P Merke; Wiebke Arlt; Richard J Ross Journal: J Clin Endocrinol Metab Date: 2009-02-17 Impact factor: 5.958
Authors: Vinicius Ludwig; Michael H Rice; William H Martin; Mark C Kelley; Dominique Delbeke Journal: Mol Imaging Biol Date: 2002-10 Impact factor: 3.488
Authors: Wiebke Arlt; Debbie S Willis; Sarah H Wild; Nils Krone; Emma J Doherty; Stefanie Hahner; Thang S Han; Paul V Carroll; Gerry S Conway; D Aled Rees; Roland H Stimson; Brian R Walker; John M C Connell; Richard J Ross Journal: J Clin Endocrinol Metab Date: 2010-08-18 Impact factor: 5.958
Authors: Rachel Wurth; Amit Tirosh; Crystal D C Kamilaris; Jancarlos Camacho; Fabio R Faucz; Andrea Gutierrez Maria; Annabel Berthon; Georgios Z Papadakis; Naris Nilubol; Ahmed Hamimi; Ahmed M Gharib; Andrew Demidowich; Mihail Zilbermint; Graeme Eisenhofer; Leah Braun; Martin Reincke; Constantine A Stratakis; Fady Hannah-Shmouni Journal: J Endocr Soc Date: 2020-10-29
Authors: Irina Bacila; Neil Richard Lawrence; Sundus Mahdi; Sabah Alvi; Timothy D Cheetham; Elizabeth Crowne; Urmi Das; Mehul Tulsidas Dattani; Justin H Davies; Evelien Gevers; Ruth E Krone; Andreas Kyriakou; Leena Patel; Tabitha Randell; Fiona J Ryan; Brian Keevil; S Faisal Ahmed; Nils P Krone Journal: Eur J Endocrinol Date: 2022-09-16 Impact factor: 6.558